TY - JOUR AU - Herman, Bianka Edina AU - Gardi, János AU - Julesz, János AU - Tömböly, Csaba AU - Szánti-Pintér, Eszter AU - Fehér, Klaudia AU - Skodáné Földes, Rita AU - Szécsi, Mihály TI - Steroidal ferrocenes as potential enzyme inhibitors of the estrogen biosynthesis JF - BIOLOGIA FUTURA J2 - BIOL FUTURA VL - 71 PY - 2020 IS - 3 SP - 249 EP - 264 PG - 16 SN - 2676-8615 DO - 10.1007/s42977-020-00023-7 UR - https://m2.mtmt.hu/api/publication/31365295 ID - 31365295 LA - English DB - MTMT ER - TY - JOUR AU - Szabó, Renáta AU - Ménesi, Rudolf AU - Molnár, Andor AU - Szalai, Zita AU - Daruka, Lejla AU - Tóth, Gábor AU - Gardi, János AU - Gálfi, Márta AU - Börzsei, Denise AU - Kupai, Krisztina AU - Juhász, Anna AU - Radács, Marianna AU - László, Ferenc AU - Varga, Csaba AU - Pósa, Anikó TI - New Metabolic Influencer on Oxytocin Release: The Ghrelin JF - MOLECULES J2 - MOLECULES VL - 24 PY - 2019 IS - 4 PG - 8 SN - 1420-3049 DO - 10.3390/molecules24040735 UR - https://m2.mtmt.hu/api/publication/30446615 ID - 30446615 N1 - The study was supported by GINOP-2.3.2-15-2016-00062 and the Ministry of Human Capacities, Hungary grant 20391-3/2018/FEKUSTRAT is acknowledged. Furthermore, this work has been supported by the European Union, cofinanced by the European Social Fund EFOP-3.6.2-16-2017-00009. LA - English DB - MTMT ER - TY - JOUR AU - Schuster, Sabine AU - Biri-Kovács, Beáta AU - Szeder, Bálint AU - Buday, László AU - Gardi, János AU - Szabó, Zsuzsanna AU - Halmos, Gábor AU - Mező, Gábor TI - Enhanced In Vitro Antitumor Activity of GnRH-III-Daunorubicin Bioconjugates Influenced by Sequence Modification JF - PHARMACEUTICS J2 - PHARMACEUTICS VL - 10 PY - 2018 IS - 4 PG - 19 SN - 1999-4923 DO - 10.3390/pharmaceutics10040223 UR - https://m2.mtmt.hu/api/publication/30445256 ID - 30445256 N1 - Funding Agency and Grant Number: European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant [642004]; National Research, Development and Innovation Office [NKFIH K119552, NVKP_16-1-2016-0036]; Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within University of Debrecen [20428-3/2018/FEKUTSTRAT]; European Union; European Regional Development Fund; MedInProt; [GINOP-2.3.2-15-2016-00043] Funding text: This work was supported by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant No. 642004; and by the National Research, Development and Innovation Office under grant NKFIH K119552 and NVKP_16-1-2016-0036. The work is also supported by the GINOP-2.3.2-15-2016-00043 (G.H.) project and by the Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within the framework of the Biotechnology Thematic Programme 20428-3/2018/FEKUTSTRAT of the University of Debrecen (G.H.). The project is co-financed by the European Union and the European Regional Development Fund. Financial resources for the western blot detection system were provided by MedInProt. AB - Receptors for gonadotropin releasing hormone (GnRH) are highly expressed in various human cancers including breast, ovarian, endometrial, prostate and colorectal cancer. Ligands like human GnRH-I or the sea lamprey analogue GnRH-III represent a promising approach for the development of efficient drug delivery systems for targeted tumor therapy. Here, we report on the synthesis and cytostatic effect of 14 oxime bond-linked daunorubicin GnRH-III conjugates containing a variety of unnatural amino acids within the peptide sequence. All compounds demonstrated a reduced cell viability in vitro on estrogen receptor α (ERα) positive and ERα negative cancer cells. The best candidate revealed an increased cancer cell growth inhibitory effect compared to our lead-compound GnRH-III-[⁴Lys(Bu),⁸Lys(Dau=Aoa)]. Flow cytometry and fluorescence microscopy studies showed that the cellular uptake of the novel conjugate is substantially improved leading to an accelerated delivery of the drug to its site of action. However, the release of the active drug-metabolite by lysosomal enzymes was not negatively affected by amino acid substitution, while the compound provided a high stability in human blood plasma. Receptor binding studies were carried out to ensure a high binding affinity of the new compound for the GnRH-receptor. It was demonstrated that GnRH-III-[²ΔHis,³d-Tic,⁴Lys(Bu),⁸Lys(Dau=Aoa)] is a highly potent and promising anticancer drug delivery system for targeted tumor therapy. LA - English DB - MTMT ER - TY - JOUR AU - Demeter-Haludka, Vivien AU - Juhász, László AU - Kovács, Mária AU - Gardi, János AU - Végh, Ágnes TI - Is there a role of iNOS activation in the delayed antiarrhythmic effect of sodium nitrite? JF - CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY J2 - CAN J PHYSIOL PHARM VL - 95 PY - 2017 IS - 4 SP - 447 EP - 454 PG - 8 SN - 0008-4212 DO - 10.1139/cjpp-2016-0357 UR - https://m2.mtmt.hu/api/publication/3184963 ID - 3184963 N1 - Department of Pharmacology and Pharmacotherapy, University of Szeged, Albert-Szent Györgyi Medical Centre, Szeged, H-6720, Hungary First Department of Internal Medicine, University of Szeged, Albert-Szent Györgyi Medical Centre, Szeged, H-6720, Hungary Cited By :2 Export Date: 31 May 2021 CODEN: CJPPA Correspondence Address: Végh, Á.; Department of Pharmacology and Pharmacotherapy, Hungary; email: vegh.agnes@med.u-szeged.hu Chemicals/CAS: inducible nitric oxide synthase, 501433-35-8; nitrate, 14797-55-8; nitrite, 14797-65-0; sodium chloride, 7647-14-5; sodium nitrite, 7632-00-0; aminoethylisothiouronium, 151-16-6, 55818-78-5, 56-10-0; nitric oxide, 10102-43-9; Anti-Arrhythmia Agents; beta-Aminoethyl Isothiourea; Nitric Oxide; Nitric Oxide Synthase Type II; Sodium Nitrite Department of Pharmacology and Pharmacotherapy, University of Szeged, Albert-Szent Györgyi Medical Centre, Szeged, H-6720, Hungary First Department of Internal Medicine, University of Szeged, Albert-Szent Györgyi Medical Centre, Szeged, H-6720, Hungary Cited By :2 Export Date: 21 June 2021 CODEN: CJPPA Correspondence Address: Végh, Á.; Department of Pharmacology and Pharmacotherapy, Hungary; email: vegh.agnes@med.u-szeged.hu Chemicals/CAS: inducible nitric oxide synthase, 501433-35-8; nitrate, 14797-55-8; nitrite, 14797-65-0; sodium chloride, 7647-14-5; sodium nitrite, 7632-00-0; aminoethylisothiouronium, 151-16-6, 55818-78-5, 56-10-0; nitric oxide, 10102-43-9; Anti-Arrhythmia Agents; beta-Aminoethyl Isothiourea; Nitric Oxide; Nitric Oxide Synthase Type II; Sodium Nitrite AB - This study aimed to examine whether inducible nitric oxide synthase (iNOS) plays a role in the delayed antiarrhythmic effect of sodium nitrite. Twenty-one dogs were infused intravenously with sodium nitrite (0.2 micromol/kg/min) for 20 min, either in the absence (n=12) or in the presence of the iNOS inhibitor S-(2-aminoethyl)-isothiourea (AEST; total dose: 2.0 mg/kg; i.v., n=9). Control dogs (n=12) were given saline. Twenty-four hours later, all the dogs were subjected to a 25 min period occlusion of the left anterior descending (LAD) coronary artery, followed by rapid reperfusion. Dogs treated with AEST and nitrite were received again AEST prior to the occlusion. Compared to the controls, sodium nitrite markedly reduced the number of ectopic beats, the number and incidence of ventricular tachycardia and the incidence of ventricular fibrillation during occlusion and increased survival (0% vs. 50%) from the combined ischaemia and reperfusion insult. Although AEST completely inhibited iNOS activity, the nitrite induced increased NO bioavailability during occlusion was not substantially modified. Furthermore, AEST attenuated but did not completely abolish the antiarrhythmic effect of nitrite. The marked delayed antiarrhythmic effect of sodium nitrite is not entirely due to the activation of iNOS; other mechanisms may certainly play a role. LA - English DB - MTMT ER - TY - JOUR AU - Gálfi, Márta AU - Radács, Marianna AU - Molnár, Zsolt AU - Budai, I AU - Tóth, Gábor AU - Pósa, Anikó AU - Kupai, Krisztina AU - Szalai, Zita AU - Szabó, Renáta AU - Molnár, Andor AU - Gardi, János AU - Laszlo, FA AU - Varga, Csaba TI - Ghrelin-Induced Enhancement of Vasopressin and Oxytocin Secretion in Rat Neurohypophyseal Cell Cultures JF - JOURNAL OF MOLECULAR NEUROSCIENCE J2 - J MOL NEUROSCI VL - 60 PY - 2016 IS - 4 SP - 525 EP - 530 PG - 6 SN - 0895-8696 DO - 10.1007/s12031-016-0850-4 UR - https://m2.mtmt.hu/api/publication/3130700 ID - 3130700 AB - The effects of ghrelin on vasopressin and oxytocin secretion were studied in 13-14-day cell cultures of isolated rat neurohypophyseal tissue. The vasopressin and oxytocin contents of the supernatant were determined by radioimmunoassay after a 1- or 2-h incubation. Significantly increased levels of vasopressin and oxytocin production were detected in the cell culture media following ghrelin administration, depending on the ghrelin doses. The oxytocin level proved to be more elevated than that of vasopressin. The increase of vasopressin and oxytocin secretion could be totally blocked by previous administration of the ghrelin receptor antagonist ([D-Lys3]-growth hormone-releasing peptide-6). Application of the ghrelin receptor antagonist after ghrelin administration proved ineffective. The results indicate that vasopressin and oxytocin release is influenced directly by the ghrelin system, and the effects of ghrelin on vasopressin and oxytocin secretion from the neurohypophyseal tissue in rats can occur at the level of the posterior pituitary. Our observations lend support to the view that neurohypophysis contains ghrelin receptors. LA - English DB - MTMT ER - TY - CONF AU - Herman, Bianka Edina AU - Szabó, Johanna AU - Bacsa, Ildikó AU - Wölfling, János AU - Schneider, Gyula AU - Mernyák, Erzsébet AU - Szécsi, Mihály AU - Gardi, János AU - Valkusz, Zsuzsanna TI - A 17β-HSD1 enzimaktivitás in vitro vizsgálata 13α-ösztron származékokkal. A Magyar Endokrinológiai és Anyagcsere Társaság XXVI. Jubileumi Kongresszusa TS - A Magyar Endokrinológiai és Anyagcsere Társaság XXVI. Jubileumi Kongresszusa T2 - A Magyar Endokrinológiai és Anyagcsere Társaság XXVI. Jubileumi Kongresszusa PB - Medicina Könyvkiadó C1 - Budapest PY - 2016 SP - 159 EP - 159 PG - 1 UR - https://m2.mtmt.hu/api/publication/3081947 ID - 3081947 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Valkusz, Zsuzsanna AU - Sepp, Krisztián AU - Gardi, János AU - Patócs, Attila Balázs TI - Screening and follow up of an extended Hungarian family with familial medullary thyroid cancer JF - ENDOCRINE ABSTRACTS J2 - ENDOCR ABSTR VL - 41 PY - 2016 SN - 1470-3947 DO - 10.1530/endoabs.41.EP1109 UR - https://m2.mtmt.hu/api/publication/3072269 ID - 3072269 LA - English DB - MTMT ER - TY - GEN AU - Valkusz, Zsuzsanna AU - Sepp, Krisztián AU - Gardi, János AU - Patócs, Attila Balázs TI - Screening and follow up of an extended Hungarian family with familial medullary thyroid cancer PY - 2016 UR - https://m2.mtmt.hu/api/publication/3072268 ID - 3072268 LA - English DB - MTMT ER - TY - CHAP AU - Szabó, N AU - Ajdukovic, JJ AU - Sakac, MN AU - Durendic, EA AU - Jovanovic-Santa, SS AU - Penov, Gasi KM AU - Gardi, János AU - Pajor, L AU - Julesz, János AU - Szécsi, Mihály ED - Szélpál, Szilárd TI - A 17α-hidroxiláz-C17,20-liáz (P45017α) enzim aktivitásának gátlása N-oxi 17-pikolinilidén szteroid származékokkal T2 - Innováció a Természettudományban – Doktorandusz konferencia PB - Magyar Kémikusok Egyesülete Biokémiai Szakosztály CY - Szeged SN - 9789639970632 PY - 2015 SP - 41 EP - 41 PG - 1 UR - https://m2.mtmt.hu/api/publication/3023632 ID - 3023632 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kiscsatári, Laura AU - Varga, Zoltán AU - Molnár-Gáspár, Renáta AU - Görbe, Anikó AU - Ferdinandy, Péter AU - Gardi, János AU - Kahán, Zsuzsanna TI - A növekedésihormon-felszabadító hormon (GHRH) receptorok potenciális szerepe radioaktív szívkárosodás esetén JF - MAGYAR ONKOLÓGIA J2 - MAGYAR ONKOLÓGIA VL - 59 PY - 2015 IS - 2 SP - 169 EP - 170 PG - 2 SN - 0025-0244 UR - https://m2.mtmt.hu/api/publication/2902081 ID - 2902081 N1 - http://huon.hu/2015/59/2/0162/0162a.pdf LA - Hungarian DB - MTMT ER -